
Science and Innovation at Cancer Research UK
@crukresearch
We're here to support our broad cancer research community of 4,000 scientists and clinicians. For general Cancer Research UK news & fundraising follow @CR_UK
ID: 2829265331
http://cruk.org/science 14-10-2014 10:19:10
20,20K Tweet
25,25K Followers
1,1K Following


[2/3] Christopher Fox received an endorsement for the phase 2 RADICAL trial using four novel prognostic tools to identify patients with high-risk large B-cell #lymphoma & evaluating outcomes of adding epcoritamab to standard chemo-immunotherapy. Chris Fox | University Hospital Southampton ๐
![Science and Innovation at Cancer Research UK (@crukresearch) on Twitter photo [2/3]
Christopher Fox received an endorsement for the phase 2 RADICAL trial using four novel prognostic tools to identify patients with high-risk large B-cell #lymphoma & evaluating outcomes of adding epcoritamab to standard chemo-immunotherapy.
<a href="/ProfChrisPFox/">Chris Fox</a> | <a href="/UHSFT/">University Hospital Southampton ๐</a> [2/3]
Christopher Fox received an endorsement for the phase 2 RADICAL trial using four novel prognostic tools to identify patients with high-risk large B-cell #lymphoma & evaluating outcomes of adding epcoritamab to standard chemo-immunotherapy.
<a href="/ProfChrisPFox/">Chris Fox</a> | <a href="/UHSFT/">University Hospital Southampton ๐</a>](https://pbs.twimg.com/media/GmUi8HjaAAc3_4W.jpg)



Are you a cancer prevention researcher uncovering new insights in the field? Share your work with a global audience at #PrevConf25. ๐จ Submit your abstract by 21 March. Submit abstract: bit.ly/4h8H64z American Cancer Society | National Cancer Institute





๐จ Abstract submissions for #PrevConf25 close today! Don't miss this chance to present your prevention research to a global audience at the Cancer Prevention Research Conference this summer. Submit abstract: bit.ly/4h8H64z American Cancer Society | National Cancer Institute





[2/4] Karin Hellner gained a Biology to Prevention Award to develop and test the immunogenicity of an mRNA vaccine against all oncogenic human papillomaviruses to treat persisting infections in patients undergoing resection for #cervicalcancer. #CRUKFunded University of Oxford
![Science and Innovation at Cancer Research UK (@crukresearch) on Twitter photo [2/4]
Karin Hellner gained a Biology to Prevention Award to develop and test the immunogenicity of an mRNA vaccine against all oncogenic human papillomaviruses to treat persisting infections in patients undergoing resection for #cervicalcancer.
#CRUKFunded
<a href="/UniofOxford/">University of Oxford</a> [2/4]
Karin Hellner gained a Biology to Prevention Award to develop and test the immunogenicity of an mRNA vaccine against all oncogenic human papillomaviruses to treat persisting infections in patients undergoing resection for #cervicalcancer.
#CRUKFunded
<a href="/UniofOxford/">University of Oxford</a>](https://pbs.twimg.com/media/Gm4q_2MWgAAAd4I.jpg)

[3/4] Rebecca Fitzgerald & John Lizhe Zhuang will uncover mechanisms of proliferation in hereditary diffuse #gastriccancer to identify therapeutic targets & reduce life-altering gastrectomies. #CRUKFunded Rebecca Fitzgerald Lab | Rebecca Fitzgerald | John Lizhe Zhuang | Cambridge University
![Science and Innovation at Cancer Research UK (@crukresearch) on Twitter photo [3/4]
Rebecca Fitzgerald & John Lizhe Zhuang will uncover mechanisms of proliferation in hereditary diffuse #gastriccancer to identify therapeutic targets & reduce life-altering gastrectomies.
#CRUKFunded
<a href="/RFitzgerald_lab/">Rebecca Fitzgerald Lab</a> | <a href="/RC_Fitzgerald/">Rebecca Fitzgerald</a> | <a href="/johnlzhuang/">John Lizhe Zhuang</a> | <a href="/Cambridge_Uni/">Cambridge University</a> [3/4]
Rebecca Fitzgerald & John Lizhe Zhuang will uncover mechanisms of proliferation in hereditary diffuse #gastriccancer to identify therapeutic targets & reduce life-altering gastrectomies.
#CRUKFunded
<a href="/RFitzgerald_lab/">Rebecca Fitzgerald Lab</a> | <a href="/RC_Fitzgerald/">Rebecca Fitzgerald</a> | <a href="/johnlzhuang/">John Lizhe Zhuang</a> | <a href="/Cambridge_Uni/">Cambridge University</a>](https://pbs.twimg.com/media/Gm4rDaKbwAE2VtY.jpg)

[4/4] Andrew Gilmore, Sacha Howell, Susan Astley Theodossiadis & Sankari Nagarajan will identify mammographic and genetic markers of response to preventive tamoxifen in #breastcancer to inform novel prevention strategies for resistant patients. #CRUKFunded The University of Manchester
![Science and Innovation at Cancer Research UK (@crukresearch) on Twitter photo [4/4]
Andrew Gilmore, Sacha Howell, Susan Astley Theodossiadis & Sankari Nagarajan will identify mammographic and genetic markers of response to preventive tamoxifen in #breastcancer to inform novel prevention strategies for resistant patients.
#CRUKFunded
<a href="/OfficialUoM/">The University of Manchester</a> [4/4]
Andrew Gilmore, Sacha Howell, Susan Astley Theodossiadis & Sankari Nagarajan will identify mammographic and genetic markers of response to preventive tamoxifen in #breastcancer to inform novel prevention strategies for resistant patients.
#CRUKFunded
<a href="/OfficialUoM/">The University of Manchester</a>](https://pbs.twimg.com/media/Gm4rGNOaMAE0FLL.jpg)


[2/3] Ruth Langley & John Burn will investigate platelet activation suppression by aspirin & its effect on tumour immunogenicity to expand understanding of anticancer mechanisms and validate urinary 11-dehydro-TXB2 as a biomarker for aspirin responders. #CRUKFunded Ruth Langley
![Science and Innovation at Cancer Research UK (@crukresearch) on Twitter photo [2/3]
Ruth Langley & John Burn will investigate platelet activation suppression by aspirin & its effect on tumour immunogenicity to expand understanding of anticancer mechanisms and validate urinary 11-dehydro-TXB2 as a biomarker for aspirin responders.
#CRUKFunded
<a href="/ruthjlangley/">Ruth Langley</a> [2/3]
Ruth Langley & John Burn will investigate platelet activation suppression by aspirin & its effect on tumour immunogenicity to expand understanding of anticancer mechanisms and validate urinary 11-dehydro-TXB2 as a biomarker for aspirin responders.
#CRUKFunded
<a href="/ruthjlangley/">Ruth Langley</a>](https://pbs.twimg.com/media/Gm4rLL_a4AAT8Df.jpg)

[3/3] Bernard Rachet & Ellen Nolte will evaluate how multiple sociodemographic factors interact leading to inequalities in cancer care & outcomes across England and propose strategies to reduce the impact of these inequalities. #CRUKFunded London School of Hygiene & Tropical Medicine
![Science and Innovation at Cancer Research UK (@crukresearch) on Twitter photo [3/3]
Bernard Rachet & Ellen Nolte will evaluate how multiple sociodemographic factors interact leading to inequalities in cancer care & outcomes across England and propose strategies to reduce the impact of these inequalities.
#CRUKFunded
<a href="/LSHTM/">London School of Hygiene & Tropical Medicine</a> [3/3]
Bernard Rachet & Ellen Nolte will evaluate how multiple sociodemographic factors interact leading to inequalities in cancer care & outcomes across England and propose strategies to reduce the impact of these inequalities.
#CRUKFunded
<a href="/LSHTM/">London School of Hygiene & Tropical Medicine</a>](https://pbs.twimg.com/media/Gm4rOO2WIAAv1yc.jpg)
